On the Radar: Five biotech companies to watch

Dr. Simos SimeonidisPartnering deals, regulatory actions and fresh clinical trial data make up a big part of what we cover here at FierceBiotech. So we decided to start asking some prominent market analysts to give us an inside look at what they're watching for on the near horizon. Today we start with Dr. Simos Simeonidis (pictured), the senior biotech analyst for Rodman & Renshaw, who scanned the radar for five key upcoming events and his thoughts on how they're likely to play out. He focuses on Poniard Pharmaceuticals, GTx, OncoGenex, MannKind and Rigel.

Each one of these companies is at an important crossroad in their development. Their success or failure will have a big impact on their future. Take a look and give us some feedback on what you think, and who else you'd like to hear projections from. Read the report

Suggested Articles

Just weeks after the biotech raised a $63 million round, Accent Therapeutics is striking its first Big Pharma partnership with AstraZeneca.

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.